Prognostic imaging variables for recurrent laryngeal and hypopharyngeal carcinoma treated with primary chemoradiotherapy: A systematic review and meta‐analysis

Abstract

Background In this systematic review, we aim to identify prognostic imaging variables of recurrent laryngeal or hypopharyngeal carcinoma after chemoradiotherapy. Methods A systematic search was performed in PubMed and EMBASE (1990–2020). The crude data and effect estimates were extracted for each imaging variable. The level of evidence of each variable was assessed and pooled risk ratios (RRs) were calculated. Results Twenty‐two articles were included in this review, 17 on computed tomography (CT) and 5 on magnetic resonance imaging (MRI) variables. We found strong evidence for the prognostic value of tumor volume at various cut‐off points (pooled RRs ranging from 2.09 to 3.03). Anterior commissure involvement (pooled RR 2.19), posterior commissure involvement (pooled RR 2.44), subglottic extension (pooled RR 2.25), and arytenoid cartilage extension (pooled RR 2.10) were also strong prognostic factors. Conclusion Pretreatment tumor volume and involvement of several subsites are prognostic factors for recurrent laryngeal or hypopharyngeal carcinoma after chemoradiotherapy.

Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study

“… 22 , 23 Then, Lin et al, Tang, Gong et al and Tian et al constructed nomograms for predicting survival in patients with hypopharyngeal squamous-cell carcinoma. 12 , 24 , 25 However, SPM was not included in their nomograms. Our study is the first study of SPM in patients with HPC.…”

“… 10 , 11 Smoking, drinking, HPV infection and genetic microenvironmental factors are important influences on the occurrence and development of HPC. 12 However, the risk factors for SPM in patients with HPC are unclear, and the effects of SPM have not been effectively assessed. With the increase in the number of cancer survivors, the risk of SPM in patients must be assessed to provide insights for the further treatment of cancer.…”